Ablynx NV: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Ablynx NV Announces Exercise of Warrants for EUR EUR 884,476.40
Ablynx NV announced that an additional 273,913 common shares have been issued by the Company in exchange for EUR 884,476.40 as the result of the exercise of warrants by some employees and consultants of the Company. As a result of this transaction, Ablynx NV has 48,802,115 shares outstanding.
Latest Key Developments in Biotechnology
- Recro Pharma Inc announces full exercise of underwriters' option to purchase additional shares
- Rexahn Pharmaceuticals Inc announces initial results from phase I trial of SupinoxinTM (RX-5902) for solid cancer tumors
- Tekmira Pharmaceuticals Corp proposes public offering of common stock
- La Jolla Pharmaceutical Co reports positive, top-line results from phase 2 clinical trial of gcs-100 in chronic kidney disease
- Share this
- Digg this